Literature DB >> 32792222

Pretracheal-laryngeal lymph nodes in frozen section predicting contralateral paratracheal lymph nodes metastasis.

Liguang Zhou1, Haipeng Li2, Weili Liang3, Chao Gao3, Bo Chen4.   

Abstract

BACKGROUND: There has been an ongoing debate concerning the predictors of contralateral paratracheal lymph nodes metastasis (LNM) in unilateral papillary thyroid cancer (PTC). This study aimed to explore the value of pretracheal-laryngeal lymph nodes (LNs) in frozen section in predicting contralateral paratracheal LNM.
METHODS: A total of 242 patients with unilateral PTC were enrolled in this prospective study. Patients who underwent total thyroidectomy and bilateral central lymph nodes dissection (LND) were divided into two groups according to positive or negative contralateral paratracheal LNs. Patients' demographics and clinicopathological features were compared between the two groups. Validity indexes and consistency of pretracheal-laryngeal LNs in frozen sections were calculated.
RESULTS: LNM rates in central, ipsilateral paratracheal, pretracheal-laryngeal, and contralateral paratracheal regions were 55.37%, 47.03%, 23.55% and 14.05%, respectively. Only pretracheal-laryngeal LNM, regardless of whether detected in frozen or paraffin sections, were independent risk factors for contralateral paratracheal LNM (OR = 2.707; 95% CI 1.062-6.902; P = 0.037 in frozen section; OR = 3.072; 95% CI 1.248-7.560; P = 0.015 in paraffin section). The sensitivity, specificity, false-negative rate, false-positive rate, accuracy rate, and Kappa value of pretracheal-laryngeal LNM in frozen sections for predicting pretracheal-laryngeal LNM were 87.72%, 100%, 12.28%, 0%, 97.11% and 0.916 respectively, while those for predicting contralateral paratracheal LNM were 85,29%, 89.90%, 14.71%, 10.10%, 89.22%, and 0.618 respectively.
CONCLUSION: Pretracheal-laryngeal LNs in frozen section accurately predicted contralateral paratracheal LNM, which could allow the identification of patients who can benefit from an extended central LND.
Copyright © 2020 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

Entities:  

Keywords:  Frozen section; Lymph nodes metastasis; Papillary thyroid cancer; Pretracheal and prelaryngeal sub-compartment

Mesh:

Year:  2020        PMID: 32792222     DOI: 10.1016/j.ejso.2020.06.048

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  5 in total

Review 1.  [Hemithyroidectomy or total thyroidectomy for low-risk papillary thyroid cancer? : Surgical criteria for primary and secondary choice of treatment in an interdisciplinary treatment concept].

Authors:  H Dralle; F Weber; A Machens; T Brandenburg; K W Schmid; D Führer-Sakel
Journal:  Chirurgie (Heidelb)       Date:  2022-09-19

2.  The Extent of Therapeutic Central Compartment Neck Dissection in Unilateral cT1N1a or cT2N1a Papillary Thyroid Carcinoma.

Authors:  Nan Liu; Yupeng Yang; Bo Chen; Luchuan Li; Qingdong Zeng; Lei Sheng; Bin Zhang; Weili Liang; Bin Lv
Journal:  Cancer Manag Res       Date:  2020-12-14       Impact factor: 3.989

3.  Pretracheal Lymph Node Subdivision in Predicting Contralateral Central Lymph Node Metastasis for Unilateral Papillary Thyroid Carcinoma: Preliminary Results.

Authors:  Qiang Chen; Yang Liu; Wei Lu; Lingyun Zhang; Anping Su; Feng Liu; Jingqiang Zhu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-18       Impact factor: 6.055

4.  Relationship between pretracheal and/or prelaryngeal lymph node metastasis and paratracheal and lateral lymph node metastasis of papillary thyroid carcinoma: A meta-analysis.

Authors:  Bin Wang; Chun-Rong Zhu; Hong Liu; Xin-Min Yao; Jian Wu
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

5.  Effect of Tumor Location on the Risk of Bilateral Central Lymph Node Metastasis in Unilateral 1-4 cm Papillary Thyroid Carcinoma.

Authors:  Nan Liu; Bo Chen; Luchuan Li; Qingdong Zeng; Lei Sheng; Bin Zhang; Bin Lv
Journal:  Cancer Manag Res       Date:  2021-07-20       Impact factor: 3.989

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.